HENDERSON -
Details of this event can also be found below.
Event: VolitionRx Limited Second Quarter 2023 Earnings and Business Update Conference Call
Date:
Time:
Toll/International: 1-201-493-6779
Conference ID: 13740530
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Contact:
Email: mediarelations@volition.com
Tel: +44 (0)7557 774620
(C) 2023 Electronic News Publishing, source